Danish Market Community
Our community narratives are driven by numbers and valuation.
Danish Investing Ideas
Global Weekly Picks
Probably the best stock I've seen all year.
Cash Source Summary Their revenue has had a significant upwards trajectory growing 10%+ since FY21, with these trailing twelve months growing at ~17%. This growth is not there to a degree that is unsustainable, as 10%-30% growth can be achieved over time, and their proven track record is an even better sign of success.Read more
Novo Nordisk (NVO): Is the "Easy Growth" Story Over?
31 Dec 2025 For shareholders of Novo Nordisk (NVO) , the past three years have been a masterclass in value creation. High margins, infinite demand, and a virtual monopoly in the obesity market drove the stock to record highs.Read more
EU#2 - From Humble Beginnings to Global Powerhouse
Novo Nordisk, one of the world’s leading pharmaceutical companies, has a unique and inspiring origin story rooted in personal tragedy and scientific curiosity. The company’s roots date back to the 1920s, when Danish Nobel laureate August Krogh, a renowned physiologist, and his wife Marie, who suffered from type 2 diabetes, traveled to Canada.Read more
Challenging Future for STG as Organic Sales Decline by 8.8%
Key Financial Results (Q1 2025) Reported net sales : DKK 2.0 billion ( +1.3% year-over-year ). Organic net sales growth : -8.8% , due to: Lower consumption of handmade cigars in the U.S. End of online distribution of ZYN in the U.S. Temporary supply issues caused by SAP implementation in European factories.Read more
Novo Nordisk gears up for explosive growth in weight-loss and diabetes treatments
Catalysts Most Immediate Catalyst (1–2 Years): Weight-Loss Drug Boom: Novo Nordisk’s Wegovy (semaglutide) is dominating the obesity drug market , with demand outpacing supply. Obesity treatment is becoming a major new revenue stream.Read more
Analysts Hold Alm. Brand Price Target Steady as Solvency Capital Requirement Drops
Key Takeaways Strong growth and strategic partnerships in Personal Lines are boosting market share and future revenue prospects. Repricing strategies and operational efficiencies are expected to enhance profitability, improve net margins, and boost earnings.Read more
ALK B: Chinese Partnership And Revenue Upside Will Drive Future Opportunities
Key Takeaways Expansion in pediatric allergy treatments and innovative products boosts patient reach, market share, and future revenue growth potential. Operational efficiencies, strategic partnerships, and a strong pipeline support sustainable margin improvements and portfolio diversification.Read more
Schenker Integration Will Streamline Global Logistics And Digital Systems
Key Takeaways Schenker integration and digital investment are set to boost DSV's efficiency, margins, and long-term profitability through cost reductions and operational improvements. Focus on high-growth verticals and value-added services positions DSV for sustained revenue gains, premium pricing, and increased market share.Read more
Fixed-cost Pressures Will Curb Outlook Yet Reveal Hidden Value
Key Takeaways Slow innovation and a hardware-heavy approach may lead to market share loss as rivals offer integrated software solutions, squeezing margins. Sustainability investments and high fixed costs threaten profitability, while sales challenges in key regions risk ongoing pressure on organic revenue growth and margins.Read more
